Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 5:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ON Dopaminergic Medication Clear all
Completed Phase 4 Interventional Results available

Buspirone Treatment of Anxiety in Williams Syndrome

NCT04807517
View directory record Official record
Conditions
Williams Syndrome, Anxiety
Interventions
Buspirone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 25, 2026, 5:20 AM EDT
Terminated Phase 2 Interventional Results available

Altropane Dose for Imaging Patients With Suspected Parkinson's Disease

NCT05636852
View directory record Official record
Conditions
Parkinson Disease, Movement Disorders
Interventions
Altropane (123I) Injection
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
4
States / cities
Baltimore, Maryland • Rochester, Minnesota • Jackson, Mississippi + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Sep 25, 2026, 5:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression

NCT00953745
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Aripiprazole, Placebo Capsule, Placebo Tablet
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 18, 2018 · Synced Sep 25, 2026, 5:20 AM EDT
Active, not recruiting Phase 1 Interventional

Enhancing Gait Using Alternating-Frequency DBS in Parkinson Disease

NCT05022147
View directory record Official record
Conditions
Parkinson Disease, Gait Disorders, Neurologic, Disease Progression, Subthalamic Nucleus, Accidental Fall, Deep Brain Stimulation
Interventions
High-Frequency-Only Stimulation, Low-Frequency-Only Stimulation, Alternating, 50 sec High-Frequency, 10 sec Low-Frequency Stimulation, Alternating, 50 sec High-Frequency, 50 sec Low-Frequency Stimulation, Alternating, 10 sec High-Frequency, 50 sec Low-Frequency Stimulation, Alternating, 10 sec High-Frequency, 10 sec Low-Frequency Stimulation, OFF Dopaminergic Medication, ON Dopaminergic Medication
Device · Drug
Lead sponsor
James Liao
Other
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 25, 2026, 5:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability of LY03010 Compared to Listed Drug

NCT04922593
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum, Mental Disorders, Antipsychotic Agents, Tranquilizing Agents, Central Nervous System Depressants, Physiological Effects of Drugs, Psychotropic Drugs, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action
Interventions
LY03010; paliperidone palmitate, INVEGA SUSTENNA
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
281 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
9
States / cities
Garden Grove, California • Lemon Grove, California • Torrance, California + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Sep 25, 2026, 5:20 AM EDT
Terminated Phase 4 Interventional Results available

Levodopa and Exercise for Older Adults With Depression and Psychomotor Slowing

NCT04650217
View directory record Official record
Conditions
Depressive Disorder
Interventions
Carbidopa/levodopa, Placebo, Exercise training, Control
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Sep 25, 2026, 5:20 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Remediation of Impaired Self-Regulation in Patients With Mild TBI

NCT02260570
View directory record Official record
Conditions
Mild Traumatic Brain Injury
Interventions
Tolcapone, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 50 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 25, 2026, 5:20 AM EDT
Completed No phase listed Observational

Suggested Immobilization Test (SIT) Test for Early Detection of Restless Legs Syndrome (RLS) Augmentation - Proof of Concept

NCT00867893
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2012 · Synced Sep 25, 2026, 5:20 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Quantification of Parkinson's Disease Patients As a Biomarker for Classification, Prediction and Response to Treatment

NCT06586320
View directory record Official record
Conditions
Parkinson Disease
Interventions
150% of their routine home dopaminergic medications dose right in the clinic, Evaluation of mathematical models
Drug · Device
Lead sponsor
Stardots AB
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Manchester, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Sep 25, 2026, 5:20 AM EDT
Terminated Early Phase 1 Interventional

Vitamin D and Cocaine Administration

NCT04826133
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Calcitriol, Placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
30 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 25, 2026, 5:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Influence of ANS-6637 on Midazolam Pharmacokinetics in Healthy Volunteers

NCT03831971
View directory record Official record
Conditions
Opiod Use Disorder
Interventions
ANS-6637
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Sep 25, 2026, 5:20 AM EDT
Enrolling by invitation Not applicable Interventional

Connectomic Guided DBS for Parkinson's Disease

NCT06618157
View directory record Official record
Conditions
Parkinson Disease, Tremor, Dyskinesias
Interventions
Cerebellothalamic optimized deep brain stimulation, Pallidothalamic optimized deep brain stimulation, No deep brain stimulation, Usual care deep brain stimulation
Device · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 25, 2026, 5:20 AM EDT
Completed Not applicable Interventional Results available

The Effect of Horizant (Gabapentin Enacarbil) on Augmentation

NCT02642315
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
Horizant
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 25, 2026, 5:20 AM EDT
Terminated Phase 2 Interventional Results available

Vision Response to Dopamine Replacement

NCT01663935
View directory record Official record
Conditions
Albinism, Oculocutaneous Albinism
Interventions
Levodopa/carbidopa
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
3 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Sep 25, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

Reduced Carbohydrate Versus Fat in Obese Subjects

NCT00846040
View directory record Official record
Conditions
Obesity
Interventions
Reduced fat diet, Reduced carbohydrate diet, Drug: f-18 fallypride, fMRI, PET
Other · Drug · Device
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 45 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Sep 25, 2026, 5:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]

NCT04178993
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Methamphetamine, Methylphenidate, Placebo oral capsule, Duloxetine
Drug
Lead sponsor
Craig Rush
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 8, 2023 · Synced Sep 25, 2026, 5:20 AM EDT
Completed Not applicable Interventional Results available

Revitalize Cognition: Near Infrared Stimulation in Parkinson Patients

NCT06688357
View directory record Official record
Conditions
Parkinson Disease
Interventions
Active NIR-PBM (MedX 1116, MCT502), Sham NIR-PBM (MedX 1116, MCT502)
Device
Lead sponsor
University of Florida
Other
Eligibility
62 Years to 89 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 16, 2025 · Synced Sep 25, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Results available

Renal Optimization Strategies Evaluation in Acute Heart Failure and Reliable Evaluation of Dyspnea in the Heart Failure Network (ROSE) Study

NCT01132846
View directory record Official record
Conditions
Acute Heart Failure
Interventions
Placebo, Nesiritide, Dopamine
Other · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
7
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Sep 25, 2026, 5:20 AM EDT
Terminated Early Phase 1 Interventional

The Use of Sensory or Motor Cues Using Electrical Stimulation to Reduce Gait Freezing in Patients With Parkinson Disease

NCT00762814
View directory record Official record
Conditions
Parkinson Disease
Interventions
Gait tests with and without the use of a tactile sensory cue (electrical stimulation using a TENS unit)
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 25, 2026, 5:20 AM EDT
Completed Phase 1 Interventional

A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.

NCT03496870
View directory record Official record
Conditions
Parkinson Disease
Interventions
Opicapone, Carbidopa Levodopa
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Glendale, California • Long Beach, California • Farmington Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 21, 2019 · Synced Sep 25, 2026, 5:20 AM EDT
Completed Phase 2 Interventional

Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease

NCT00096720
View directory record Official record
Conditions
Parkinson Disease, Parkinsonian Syndrome
Interventions
levodopa, Mirapex (pramipexole), [123I]ß-CIT and SPECT imaging
Drug · Procedure
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
30 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
13
States / cities
Oxnard, California • Englewood, Colorado • New Haven, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2010 · Synced Sep 25, 2026, 5:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Neurobiological Drivers of Mobility Resilience: The Dopaminergic System - Supplemental Open-Label Arm

NCT06587217
View directory record Official record
Conditions
Parkinsonian Signs in Older Persons
Interventions
Carbidopa 25 mg, Carbidopa-Levodopa 25/100 mg
Drug
Lead sponsor
University of Michigan
Other
Eligibility
60 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 25, 2026, 5:20 AM EDT
Terminated Phase 4 Interventional

Assessment of Valproate on Ethanol Withdrawal

NCT03235531
View directory record Official record
Conditions
Alcohol Dependence, Alcohol Withdrawal Syndrome, Trauma, Heavy Drinking, Alcohol Use Disorder
Interventions
Valproate, Lorazepam
Drug
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 25, 2026, 5:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Dopamine on Diabetic Retinopathy

NCT02706977
View directory record Official record
Conditions
Diabetes
Interventions
Low Dose Sinemet CR, High Dose Sinemet CR, RETeval Electroretinogram (ERG) Testing, Contrast Sensitivity Testing, Visual Acuity Testing
Drug · Device · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Sep 25, 2026, 5:20 AM EDT